Cargando…

Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries

Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain sto...

Descripción completa

Detalles Bibliográficos
Autores principales: Prankerd, Richard J., Nguyen, Tri-Hung, Ibrahim, Jibriil P., Bischof, Robert J., Nassta, Gemma C., Olerile, Livesey D., Russell, Adrian S., Meiser, Felix, Parkington, Helena C., Coleman, Harold A., Morton, David A. V., McIntosh, Michelle P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871608/
https://www.ncbi.nlm.nih.gov/pubmed/24376618
http://dx.doi.org/10.1371/journal.pone.0082965
_version_ 1782296846250541056
author Prankerd, Richard J.
Nguyen, Tri-Hung
Ibrahim, Jibriil P.
Bischof, Robert J.
Nassta, Gemma C.
Olerile, Livesey D.
Russell, Adrian S.
Meiser, Felix
Parkington, Helena C.
Coleman, Harold A.
Morton, David A. V.
McIntosh, Michelle P.
author_facet Prankerd, Richard J.
Nguyen, Tri-Hung
Ibrahim, Jibriil P.
Bischof, Robert J.
Nassta, Gemma C.
Olerile, Livesey D.
Russell, Adrian S.
Meiser, Felix
Parkington, Helena C.
Coleman, Harold A.
Morton, David A. V.
McIntosh, Michelle P.
author_sort Prankerd, Richard J.
collection PubMed
description Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain storage limit the use of oxytocin in the developing world. In this study, a spray-dried ultrafine formulation of oxytocin was developed with an optimal particle size diameter (1-5 µm) to facilitate aerosolised delivery via the lungs. A powder formulation of oxytocin, using mannitol, glycine and leucine as carriers, was prepared with a volume-based median particle diameter of 1.9 µm. Oxytocin content in the formulation was assayed using high-performance liquid chromatography-mass spectroscopy and was found to be unchanged after spray-drying. Ex vivo contractility studies utilising human and ovine uterine tissue indicated no difference in the bioactivity of oxytocin before and after spray-drying. Uterine electromyographic (EMG) activity in postpartum ewes following pulmonary (in vivo) administration of oxytocin closely mimicked that observed immediately postpartum (0-12 h following normal vaginal delivery of the lamb). In comparison to the intramuscular injection, pulmonary administration of an oxytocin dry powder formulation to postpartum ewes resulted in generally similar EMG responses, however a more rapid onset of uterine EMG activity was observed following pulmonary administration (129 ± 18 s) than intramuscular injection (275 ± 22 s). This is the first study to demonstrate the potential for oxytocin to elicit uterine activity after systemic absorption as an aerosolised powder from the lungs. Aerosolised oxytocin has the potential to provide a stable and easy to administer delivery system for effective prevention and treatment of postpartum haemorrhage in resource-poor settings in the developing world.
format Online
Article
Text
id pubmed-3871608
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38716082013-12-27 Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries Prankerd, Richard J. Nguyen, Tri-Hung Ibrahim, Jibriil P. Bischof, Robert J. Nassta, Gemma C. Olerile, Livesey D. Russell, Adrian S. Meiser, Felix Parkington, Helena C. Coleman, Harold A. Morton, David A. V. McIntosh, Michelle P. PLoS One Research Article Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain storage limit the use of oxytocin in the developing world. In this study, a spray-dried ultrafine formulation of oxytocin was developed with an optimal particle size diameter (1-5 µm) to facilitate aerosolised delivery via the lungs. A powder formulation of oxytocin, using mannitol, glycine and leucine as carriers, was prepared with a volume-based median particle diameter of 1.9 µm. Oxytocin content in the formulation was assayed using high-performance liquid chromatography-mass spectroscopy and was found to be unchanged after spray-drying. Ex vivo contractility studies utilising human and ovine uterine tissue indicated no difference in the bioactivity of oxytocin before and after spray-drying. Uterine electromyographic (EMG) activity in postpartum ewes following pulmonary (in vivo) administration of oxytocin closely mimicked that observed immediately postpartum (0-12 h following normal vaginal delivery of the lamb). In comparison to the intramuscular injection, pulmonary administration of an oxytocin dry powder formulation to postpartum ewes resulted in generally similar EMG responses, however a more rapid onset of uterine EMG activity was observed following pulmonary administration (129 ± 18 s) than intramuscular injection (275 ± 22 s). This is the first study to demonstrate the potential for oxytocin to elicit uterine activity after systemic absorption as an aerosolised powder from the lungs. Aerosolised oxytocin has the potential to provide a stable and easy to administer delivery system for effective prevention and treatment of postpartum haemorrhage in resource-poor settings in the developing world. Public Library of Science 2013-12-23 /pmc/articles/PMC3871608/ /pubmed/24376618 http://dx.doi.org/10.1371/journal.pone.0082965 Text en © 2013 Prankerd et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Prankerd, Richard J.
Nguyen, Tri-Hung
Ibrahim, Jibriil P.
Bischof, Robert J.
Nassta, Gemma C.
Olerile, Livesey D.
Russell, Adrian S.
Meiser, Felix
Parkington, Helena C.
Coleman, Harold A.
Morton, David A. V.
McIntosh, Michelle P.
Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
title Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
title_full Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
title_fullStr Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
title_full_unstemmed Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
title_short Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries
title_sort pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871608/
https://www.ncbi.nlm.nih.gov/pubmed/24376618
http://dx.doi.org/10.1371/journal.pone.0082965
work_keys_str_mv AT prankerdrichardj pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT nguyentrihung pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT ibrahimjibriilp pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT bischofrobertj pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT nasstagemmac pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT olerileliveseyd pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT russelladrians pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT meiserfelix pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT parkingtonhelenac pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT colemanharolda pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT mortondavidav pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries
AT mcintoshmichellep pulmonarydeliveryofanultrafineoxytocindrypowderformulationpotentialfortreatmentofpostpartumhaemorrhageindevelopingcountries